Anne Zeleniuch-Jacquotte
Professor of Population Health and Environmental Medicine
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data
Year:
2025
Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data
Year:
2025
Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data
Year:
2024
Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data
Year:
2024
Background: There are conflicting data on whether nonalcoholic fatty liver disease (NAFLD) is associated with susceptibility to pancreatic cancer (PC). Using Mendelian randomization (MR), we investigated the relationship between genetic predisposition to NAFLD and risk for PC. Methods: Data from genome-wide association studies within the Pancreatic Cancer Cohort Consortium (PanScan; cases n=5090, controls n=8733) and the Pancreatic Cancer Case Control Consortium (PanC4; cases n=4,163, controls n=3,792) were analyzed. We used data on 68 genetic variants with four different MR methods (inverse variance weighting [IVW], MR-Egger, simple median, and penalized weighted median) separately to predict genetic heritability of NAFLD. We then assessed the relationship between each of the four MR methods and PC risk, using logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for PC risk factors, including obesity and diabetes. Results: No association was found between genetically predicted NAFLD and PC risk in the PanScan or PanC4 samples (e.g., PanScan, IVW OR=1.04, 95% CI: 0.88-1.22, MR-Egger OR=0.89, 95% CI: 0.65-1.21; PanC4, IVW OR=1.07, 95% CI: 0.90-1.27, MR-Egger OR=0.93, 95% CI: 0.67-1.28). None of the four MR methods indicated an association between genetically predicted NAFLD and PC risk in either sample. Conclusions: Genetic predisposition to NAFLD is not associated with PC risk. Impact: Given the close relationship between NAFLD and metabolic conditions, it is plausible that any association between NAFLD and PC might reflect host metabolic perturbations (e.g., obesity, diabetes, or metabolic syndrome) and does not necessarily reflect a causal relationship between NAFLD and PC.
Year:
2024
Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data
Year:
2024
Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data
Year:
2024
Figure S2 is a forest plot of the association between hypertension and endometrial cancer by study site. It displays the associations between hypertension and endometrial cancer for each study site included grouped by study type (case-control, cohort)
Year:
2024
Figure S2 is a forest plot of the association between hypertension and endometrial cancer by study site. It displays the associations between hypertension and endometrial cancer for each study site included grouped by study type (case-control, cohort)
Year:
2024
Background: The incidence rates of endometrial cancer are increasing, which may partly be explained by the rising prevalence of obesity, an established risk factor for endometrial cancer. Hypertension, another component of metabolic syndrome, is also increasing in prevalence, and emerging evidence suggests that it may be associated with the development of certain cancers. The role of hypertension independent of other components of metabolic syndrome in the etiology of endometrial cancer remains unclear. In this study, we evaluated hypertension as an independent risk factor for endometrial cancer and whether this association is modified by other established risk factors. Methods: We included 15,631 endometrial cancer cases and 42,239 controls matched on age, race, and study-specific factors from 29 studies in the Epidemiology of Endometrial Cancer Consortium. We used multivariable unconditional logistic regression models to estimate ORs and 95% confidence intervals (CI) to evaluate the association between hypertension and endometrial cancer and whether this association differed by study design, race/ethnicity, body mass index, diabetes status, smoking status, or reproductive factors. Results: Hypertension was associated with an increased risk of endometrial cancer (OR, 1.14; 95% CI, 1.09–1.19). There was significant heterogeneity by study design ( P het Conclusions: Hypertension is associated with endometrial cancer risk independently from known risk factors. Future research should focus on biologic mechanisms underlying this association. Impact: This study provides evidence that hypertension may be an independent risk factor for endometrial cancer.
Year:
2024
Year:
2024
Collaborators (51)
Rayjean Hung
University of Toronto
Neal Freedman
Branch Chief
National Cancer Institute
Christopher A. Haiman
University of Southern California
Carlo La Vecchia
Professor of Epidemiology
Università degli Studi di Torino
Ian M. Thompson
University of Texas Health Science Center at San Antonio
Anna E. Prizment
Faculty, Associate Professor
University of Minnesota
Xiao‐Ou Shu
Vanderbilt University Medical Center
Lynne Wilkens
Professor
University of Hawaii at Manoa
Sven Sandin
Associate Professor
Karolinska Institutet
Carlotta Sacerdote
Docenti di ruolo di Ia fascia
Università degli Studi del Piemonte Orientale Amedeo Avogadro
Anne Tjonneland
Professor
Københavns Universitet
Fulvio Ricceri
University of Turin
Piet van den Brandt
Professor of Epidemiology
University of Maastricht
P. M. Webb
Group Leader
QIMR Berghofer Medical Research Institute
Noah Peeri
Assistant Professor
The University of Texas MD Anderson Cancer Center
Tracy O'Mara
Team Head
QIMR Berghofer Medical Research Institute
Ulrike Peters
Fred Hutchinson Cancer Research Center
Julie R Palmer
Boston University School of Medicine
Leo Schouten
University of Maastricht
Wei Zheng
-
Miquel Porta
-
Peter Kraft
Professor
Harvard T.H. Chan School of Public Health
Kari Rabe
Assistant Professor of Biostatistics
Mayo Clinic
Stephen Chanock
National Institutes of Health
Alison Klein
Professor
-
Linda Cook
Professor
University of Colorado Cancer Center
Federico Canzian
Group Leader
Deutsches Krebsforschungszentrum
Herbert Yu
Researcher/Professor
University of Hawaii at Manoa
Martijn C.G.J. Brouwers
-
Fabio Parazzini
University of Milan
Michele L. Cote
Indiana University
Thilo Hackert
University Hospital Heidelberg
Elio Riboli
Professor of Cancer Epidemiology
Imperial College London
Rachael Solomon
Senior Eoidemiologist
Division of Cancer Epidemiology and Genetics, National Cancer Institute
Jean Wactawki-Wende
Dean, Suny Distinguished Professor
University at Buffalo
Malin Sund
Professor/Consultant
University of Helsinki
Loic Le Marchand
Professor
University of Hawaii
Donghui Li
Professor
The University of Texas MD Anderson Cancer Center
Jo Freudenheim
SUNY Distinguished Professor and Associate Dean
University at Buffalo
Alan Arslan
Associate Professor
NYU Langone Medical Center
Eva Negri
Associate professor
University of Bologna
Nuria Malats
Group Leader
Centro Nacional de Investigaciones Oncológicas
Kala Visvanathan
Professor
Johns Hopkins University
Manal M. Hassan
Professor
The University of Texas MD Anderson Cancer Center
Veronica Setiawan
Associate Professor
University of Southern California
Susan J. Jordan
Associate Profesor
University of Queensland
Charles Kooperberg
Fred Hutchinson Cancer Research Center
Lingeng Lu
Yale School of Public Health
Kimberly A. Bertrand
Associate Professor of Medicine
Boston University
Graham Giles
Head of Research
-
Manolis Kogevinas
Senior Researcher
Barcelona Institute for Global Health
Make your next move.
Prepare your application
Review drafts before you send them.